Edition:
United States

Novan Inc (NOVN.OQ)

NOVN.OQ on NASDAQ Stock Exchange Global Market

4.84USD
8 Dec 2017
Change (% chg)

$-0.03 (-0.62%)
Prev Close
$4.87
Open
$4.90
Day's High
$4.95
Day's Low
$4.70
Volume
13,103
Avg. Vol
16,055
52-wk High
$29.77
52-wk Low
$3.52

Latest Key Developments (Source: Significant Developments)

Novan announces first patient dosed in phase 1B Atopic Dermatitis trial With Sb414
Tuesday, 5 Dec 2017 08:35am EST 

Dec 5 (Reuters) - Novan Inc ::NOVAN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B ATOPIC DERMATITIS TRIAL WITH SB414.NOVAN INC - ‍ TOP LINE RESULTS FROM PHASE 1B ATOPIC DERMATITIS TRIAL WITH SB414​ ARE TARGETED FOR Q3 OF 2018.NOVAN INC - ‍TOP LINE RESULTS ARE TARGETED FOR Q2 OF 2018 FROM PREVIOUSLY ANNOUNCED PHASE 1B CLINICAL TRIAL WITH SB414 FOR TREATMENT OF PSORIASIS​.  Full Article

Novan says ‍agreed to business structure to enable development of SB204 via 3rd party financing and execution
Tuesday, 7 Nov 2017 08:05am EST 

Nov 7 (Reuters) - Novan Inc ::Novan Inc -‍agreed to business structure to enable development of SB204 via 3rd party financing, 3rd party execution of additional Phase 3 pivotal trial​.Novan Inc - ‍proposed Phase 3 trial would be executed by third party's dermatology drug development team​.Novan Inc - a ‍new entity established by third party to provide capital to fund, expertise to execute additional Phase 3 pivotal trial for sb204​.  Full Article

Novan acquires IP rights to treat viral malignancies with nitric oxide
Wednesday, 18 Oct 2017 07:05am EDT 

Oct 18 (Reuters) - Novan Inc :Novan acquires IP rights to treat viral malignancies with nitric oxide.Novan Inc- ‍ Has initiated clinical development of company's nitric oxide platform in field of immunology​.Novan Inc- ‍Top line results for phase 1b trial of co's nitric oxide platform​ are expected in Q2 of 2018.Novan Inc- ‍Targeting to begin phase 1b trial with SB414 in adults with atopic dermatitis before year end with top line results expected in Q3 of 2018​.  Full Article

Novan Inc says files for mixed shelf of upto $150 million ‍​
Monday, 2 Oct 2017 04:32pm EDT 

Oct 2 (Reuters) - Novan Inc :Novan Inc says files for mixed shelf of upto $150 million - SEC filing‍​ ‍​.Novan Inc says in addition, may offer and sell up to 2.62 million shares common stock offered by selling stockholder.  Full Article

Novan conducts guidance meeting with FDA on SB204 development program
Monday, 25 Sep 2017 08:00am EDT 

Sept 25 (Reuters) - Novan Inc :Novan conducts guidance meeting with FDA on SB204 development program.Novan Inc - ‍concluded a guidance meeting with U.S FDA regarding SB204 for treatment of acne vulgaris​.Novan Inc - ‍FDA advised that an additional pivotal trial should be conducted​.  Full Article

Novan Inc director ‍Robert Ingram reports open market purchase of 12,000 shares of co's common stock - SEC filing​
Tuesday, 29 Aug 2017 04:52pm EDT 

Aug 29 (Reuters) - Novan Inc :Novan Inc director ‍Robert Ingram reports open market purchase of 12,000 shares of co's common stock - SEC filing​.Novan Inc director Robert Ingram bought 3,535 shares on Aug 25 at $4.25 per share and 8,465 shares on Aug 29 at $4.70 per share - SEC filing.  Full Article

Novan says non-executive director Kelly Martin will assume role of CEO on interim basis
Monday, 5 Jun 2017 08:30am EDT 

June 5 (Reuters) - Novan Inc :Novan announces leadership adjustments and business update.Novan - nate stasko, current ceo, will now focus "his efforts and considerable scientific talent as "president & chief scientific officer" of novan".Bob ingram, current chairman of company's board of directors, will now serve as non-employee executive chairman of board.Kelly martin, currently a non-executive director, will assume role of chief executive officer of novan on an interim basis.Kent geer will become lead independent director of company and continue in his role as chairman of audit committee.Continues to believe that company's cash on hand is sufficient to fund operations at least through end of 2017.  Full Article

Novan qtrly loss per share $0.73
Friday, 12 May 2017 09:05am EDT 

May 12 (Reuters) - Novan Inc :Novan reports first quarter 2017 financial results.Qtrly loss per share $0.73.Novan inc - continues to believe that company's cash on hand is sufficient to fund operations at least through end of 2017.Novan - are exploring a number of potential financing options, including partnering activities, in efforts to continue advancement of product candidates.  Full Article

Novan presents safety data for SB204 program
Thursday, 27 Apr 2017 09:14am EDT 

April 27 (Reuters) - Novan Inc :Novan presents safety data for SB204 program.Novan inc- in general, all doses of SB204 were well tolerated and not associated with any significant safety issues in these trials.Novan inc - expects to report additional safety data from long-term safety trial, NI-AC303 in Q3 of this year.Novan inc- NDA submission targeted in Q1 of 2018 for sb204.Novan inc- intends to pursue a pre-submission meeting with fda to discuss entirety of SB204 development program in q3 of 2017.  Full Article

Novan reports positive topline results with SB208 in phase 2 trial
Wednesday, 12 Apr 2017 06:07am EDT 

Novan Inc : Novan reports positive topline results with SB208 in phase 2 trial . Novan Inc - SB208 gel, at both 4% and 16% concentrations, demonstrated a statistically significant effect (p<0.05) versus vehicle in a clinical trial . "Results from this phase 2 trial with SB208 confirm fungicidal activity of nitric oxide observed in our preclinical studies" . Novan - Based on data from SB208 phase 2 dose-ranging trial, co will evaluate late stage development opportunities in superficial cutaneous fungal infections .Novan - Will evaluate opportunities such as a phase 2 trial in patients with onychomycosis, to be initiated as early as second half of 2017.  Full Article

BRIEF-Novan announces first patient dosed in phase 1B Atopic Dermatitis trial With Sb414

* NOVAN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B ATOPIC DERMATITIS TRIAL WITH SB414